IN THE CLAIMS:

- 1 16. (Previously canceled)
- 17. (Currently amended) A <u>synergistic antineoplastic composition</u> [product] containing an alkylating anthracycline of formula la or lb:

and an antimetabolite compound as a combined preparation that has a synergistic antineoplastic effect for use in treatment of tumors in mammals.

- 18. (Currently amended) The [product] <u>composition</u> according to claim 17, further containing a pharmaceutically acceptable carrier or excipient.
- 19. (Currently canceled) The product according to claim 17 or claim 18, wherein the mammal is a human.
- 20. (Currently amended) The [product] <u>composition</u> according to claim 17 or claim 18 wherein the alkylating anthracycline is a 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methanesulfonyl daunorubicin.
- 21. (Currently amended) [A product] <u>The composition</u> according to claim 17 or claim 18 wherein the antimetabolite compound is a cytidine analog.

- 22. (Currently amended) [A product] <u>The composition</u> according to claim 17 or claim 18 wherein the antimetabolite compound is a 5-fluoropyrimidine.
- 23. (Currently amended) [A product] <u>The composition</u> according to claim 21 wherein the cytidine analog is gemcitabine.
- 24. (Currently amended) [A product] <u>The composition</u> according to claim 22 wherein the 5-fluoropyrimidine is 5-fluorouracil.
- 25. (Previously amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and, as an active ingredient, an alkylating anthracycline of formula la or lb as defined in claim 17 and an antimetabolite compound that has a synergistic antineoplastic effect in mammals.
- 26. (Currently canceled) A pharmaceutical composition according to claim 25 wherein the mammal is a human.
- 27 (Currently amended) [A] <u>The pharmaceutical composition according to claim 25 or claim 26 wherein the antimetabolite compound is 5-fluorouricil or gemcitabine.</u>
- 28. (Previously presented) A method for treating tumors in a mammal in need thereof, comprising administering the alkylating anthracycline of formula la or lb and an antimetabolite compound as claimed in claim 17 or claim 18 to said mammal in a synergistic antineoplastic effective amount.
- 29. (Previously presented) The method according to claim 28 wherein the mammal is a human.
- 30. (Currently twice amended) The method according to claim 28 [or claim 29] wherein the antimetabolite compound is 5-fluorouracil or gemcitabine.
- 31. (Previously canceled)
- 32. (Currently amended) [A method for treatment of metastasis in a mammal in need thereof, comprising administering the alkylating anthracycline of formula la or lb and an

antimetabolite compound as claimed in claim 17 or claim 18 to said mammal in a synergistic antineoplastic effective amount] The method according to claim 29 wherein the antimetabolite compound is 5-fluorouracil or gemcitabine.

- 33. (Currently canceled) The method according to claim 32 wherein the mammal is a human.
- 34. (Currently canceled) The method according to claim 32 or claim 33 wherein the antimetabolite compound is 5-fluorouracil or gemcitabine.
- 35. (Previously canceled)
- 36. (Previously presented) A method for treating a tumor by the inhibition of angiogenesis in a mammal in need thereof, comprising administering the alkylating anthracycline of formula la or lb and an antimetabolite compound as claimed in claim 17 or claim 18 to said mammal in a synergistic antineoplastic effective amount.
- 37. (Previously presented) The method according to claim 36 wherein the mammal is a human.
- 38. (Currently twice amended) The method according to claim 36 [or claim 37] wherein the antimetabolite compound is 5-fluorouracil or gemcitabine.
- 39. (Canceled)
- 40. (New) The method according to claim 37 wherein the antimetabolite compound is 5-fluorouracil or gemcitabine.
- 41. (New) A method for treatment of metastasis in a mammal in need thereof, comprising administering the alkylating anthracycline of formula la or lb and an antimetabolite compound as claimed in claim 17 or claim 18 to said mammal in a synergistic antineoplastic effective amount.
- 42. (New) The method according to claim 41 wherein the mammal is a human.

- 43. (New) The method according to claim 41 wherein the antimetabolite compound is 5-fluorouracil or gemcitabine.
- 44. (New) The method according to claim 42 wherein the antimetabolite compound is 5-fluorouracil or gemcitabine.